Clinical Trial Update: Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial results indicate that routine pre-medications to prevent hypersensitivity reactions may be safely stopped for patients with breast cancer treate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2025-08-20